Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Cancer Research

Background:

• Overexpression of the ATP-binding cassette transporter G2 (ABCG2) contributes to multidrug resistance (MDR) in cancer, reducing chemotherapy effectiveness.
• Targeting ABCG2 with selective inhibitors is a key strategy to enhance cancer treatment outcomes.

Purpose of the Study:

• To design and synthesize novel compounds as potential ABCG2 inhibitors.
• To evaluate the inhibitory activity, selectivity against ABCB1 (P-gp), and toxicity of the synthesized compounds.
• To identify potent and selective ABCG2 inhibitors for overcoming multidrug resistance.

Main Methods:

• Synthesis of a library of 38 novel heteroaryl-phenyl scaffold compounds and 12 precursors.
• In vitro evaluation of ABCG2 inhibition and selectivity against ABCB1 (P-gp).
• Assessment of compound toxicity and their ability to reverse ABCG2-mediated drug resistance.

Main Results:

• Structure-activity relationship studies indicated that a phenylheteroaryl-phenylamide scaffold is crucial for ABCG2 inhibition.
• Compound 43 demonstrated potent ABCG2 inhibition (IC50 = 61 nM) with high selectivity.
• Compound 43 exhibited low intrinsic toxicity and reversed ABCG2-mediated drug resistance at a concentration of 0.1 μM.

Conclusions:

• The designed heteroaryl-phenylamide compounds are effective inhibitors of ABCG2.
• Compound 43 represents a promising lead candidate for developing novel agents to combat multidrug resistance in cancer therapy.
• Further investigation into compound 43 could lead to improved chemotherapy regimens.